![Frontiers | Molecular Aberrations Stratify Grade 2 Astrocytomas Into Several Rare Entities: Prognostic and Therapeutic Implications Frontiers | Molecular Aberrations Stratify Grade 2 Astrocytomas Into Several Rare Entities: Prognostic and Therapeutic Implications](https://www.frontiersin.org/files/Articles/866623/fonc-12-866623-HTML/image_m/fonc-12-866623-g001.jpg)
Frontiers | Molecular Aberrations Stratify Grade 2 Astrocytomas Into Several Rare Entities: Prognostic and Therapeutic Implications
Fédération Malagasy de Basket Ball - .Deadline mutation U14 : 03 Août - Aucune demande de mutation ne sera plus acceptée .Fiches d'engagement pour qualification remplies correctement (date de naissance - numéro
![Post Hoc Analysis of Objective Response Rate by Mismatch Repair Protein Dimer Loss/Mutation Status in Patients with Mismatch Repair Deficient Endometrial Cancer Treated with Dostarlimab | GSK Post Hoc Analysis of Objective Response Rate by Mismatch Repair Protein Dimer Loss/Mutation Status in Patients with Mismatch Repair Deficient Endometrial Cancer Treated with Dostarlimab | GSK](https://presentations.gsk.com/wp-content/uploads/2022/10/Dost63699_ESGO2022_GARNET-Mut-Meth_Figure-2.jpg)
Post Hoc Analysis of Objective Response Rate by Mismatch Repair Protein Dimer Loss/Mutation Status in Patients with Mismatch Repair Deficient Endometrial Cancer Treated with Dostarlimab | GSK
![Human ARHGEF9 intellectual disability syndrome is phenocopied by a mutation that disrupts collybistin binding to the GABAA receptor α2 subunit | Molecular Psychiatry Human ARHGEF9 intellectual disability syndrome is phenocopied by a mutation that disrupts collybistin binding to the GABAA receptor α2 subunit | Molecular Psychiatry](https://media.springernature.com/full/springer-static/image/art%3A10.1038%2Fs41380-022-01468-z/MediaObjects/41380_2022_1468_Fig1_HTML.png)
Human ARHGEF9 intellectual disability syndrome is phenocopied by a mutation that disrupts collybistin binding to the GABAA receptor α2 subunit | Molecular Psychiatry
![Circulating tumour DNA analysis to direct therapy in advanced breast cancer (plasmaMATCH): a multicentre, multicohort, phase 2a, platform trial - The Lancet Oncology Circulating tumour DNA analysis to direct therapy in advanced breast cancer (plasmaMATCH): a multicentre, multicohort, phase 2a, platform trial - The Lancet Oncology](https://www.thelancet.com/cms/attachment/33f1ed32-8728-4ffc-a4c1-f49d5f88b246/gr1_lrg.gif)
Circulating tumour DNA analysis to direct therapy in advanced breast cancer (plasmaMATCH): a multicentre, multicohort, phase 2a, platform trial - The Lancet Oncology
Puma Biotechnology Expands Cohort in Phase II Trial of PB272 in HER2 Mutation Positive Cancer Patients
![Frontiers | Implications of BRAF V600E mutation in gliomas: Molecular considerations, prognostic value and treatment evolution Frontiers | Implications of BRAF V600E mutation in gliomas: Molecular considerations, prognostic value and treatment evolution](https://www.frontiersin.org/files/MyHome%20Article%20Library/1067252/1067252_Thumb_400.jpg)
Frontiers | Implications of BRAF V600E mutation in gliomas: Molecular considerations, prognostic value and treatment evolution
![Treatment Options for Non-Small Cell Lung Cancer Harboring Uncommon *EGFR* Mutations | Published in healthbook TIMES Oncology Hematology Treatment Options for Non-Small Cell Lung Cancer Harboring Uncommon *EGFR* Mutations | Published in healthbook TIMES Oncology Hematology](https://s3.amazonaws.com/production.scholastica/attachment/93851/large/image10.jpeg?X-Amz-Algorithm=AWS4-HMAC-SHA256&X-Amz-Credential=AKIAQP35HG4CYCAIE5XO%2F20230706%2Fus-east-1%2Fs3%2Faws4_request&X-Amz-Date=20230706T021746Z&X-Amz-Expires=604800&X-Amz-SignedHeaders=host&X-Amz-Signature=6cbd7643ac89fffd08663396b29d8e0ef37a871ce1cb918fae52dd9d5153297d)
Treatment Options for Non-Small Cell Lung Cancer Harboring Uncommon *EGFR* Mutations | Published in healthbook TIMES Oncology Hematology
![Treatment Options for Non-Small Cell Lung Cancer Harboring Uncommon *EGFR* Mutations | Published in healthbook TIMES Oncology Hematology Treatment Options for Non-Small Cell Lung Cancer Harboring Uncommon *EGFR* Mutations | Published in healthbook TIMES Oncology Hematology](https://s3.amazonaws.com/production.scholastica/attachment/93847/large/image2.jpeg?X-Amz-Algorithm=AWS4-HMAC-SHA256&X-Amz-Credential=AKIAQP35HG4CYCAIE5XO%2F20230706%2Fus-east-1%2Fs3%2Faws4_request&X-Amz-Date=20230706T021746Z&X-Amz-Expires=604800&X-Amz-SignedHeaders=host&X-Amz-Signature=ba65c27e2182b63ea427fbfea34627d0d13cf401c3fddf4ea75cf020f34b1f63)
Treatment Options for Non-Small Cell Lung Cancer Harboring Uncommon *EGFR* Mutations | Published in healthbook TIMES Oncology Hematology
![Dabrafenib plus trametinib in patients with BRAFV600E-mutant low-grade and high-grade glioma (ROAR): a multicentre, open-label, single-arm, phase 2, basket trial - The Lancet Oncology Dabrafenib plus trametinib in patients with BRAFV600E-mutant low-grade and high-grade glioma (ROAR): a multicentre, open-label, single-arm, phase 2, basket trial - The Lancet Oncology](https://www.thelancet.com/cms/asset/d6622fb0-9069-436c-a3bd-a10885c23e2c/gr1.jpg)